CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

• John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter
• The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023
• CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials in mid-2023
• Through its research, CNS looks to tap into the brain tumor therapeutics market, which is expected to be valued at $3.4 billion by 2025, up from $2.25 billion in 2019

On September 30, 2022, CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, Glioblastoma Multiforme (“GBM”), and neuro-oncology, released its financial results for the third quarter of the 2022 financial year (“Q3 2022”). While making the announcement, John Climaco, CNS’s CEO, lauded the company’s progress, highlighting the successful expansion of its pivotal Berubicin trial into Europe within the quarter. He further noted how the move was integral to the company achieving interim analysis by mid-2023 which, he believes, will be a transformational milestone (https://ibn.fm/HtX2Y).

CNS has, since its inception, shown its commitment to solving the unmet need associated with the treatment of GBM. This condition affects approximately 13,000 people in the United States each year. It is estimated that up to 50% of original malignant tumors of the central nervous system (“CNS”) are…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.